Core Insights - SciSparc Ltd. has announced a collaboration with Clearmind Medicine Inc. that has resulted in the publication of an international patent application under the Patent Cooperation Treaty (PCT) [1] - The patent application covers a combination therapy of Clearmind's 5-methoxy-2-aminoindane (MEAI) and SciSparc's Palmitoylethanolamide (PEA) aimed at treating metabolic syndrome and obesity [2] - Metabolic syndrome affects up to one-third of U.S. adults, increasing the risk of serious health issues such as heart disease and type 2 diabetes [3] - The collaboration has led to the filing of 13 patent families across multiple jurisdictions, focusing on innovative therapies for mental health disorders and metabolic conditions [4] Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing cannabinoid-based therapies, with ongoing programs targeting Tourette Syndrome, Alzheimer's disease, autism, and status epilepticus [5] - Clearmind Medicine Inc. is a clinical-stage psychedelic pharmaceutical biotech company dedicated to developing psychedelic-derived therapeutics for health issues like alcohol use disorder, with a portfolio of 19 patent families [6]

Core Viewpoint - SciSparc Ltd. is progressing with its proposed merger with AutoMax Motors Ltd., which will enhance its portfolio in the electric vehicle sector while maintaining its focus on cannabinoid pharmaceuticals [1][2]. Group 1: Merger Details - SciSparc and AutoMax entered into a merger agreement in April 2024, where SciSparc will acquire 100% of AutoMax's share capital through a reverse merger [2]. - The merger is subject to customary closing conditions, including shareholder approvals from both companies and Israeli court approval [2]. - Special meetings for shareholder votes on the merger are scheduled for August 25, 2025, for SciSparc and August 28, 2025, for AutoMax [2]. Group 2: Regulatory Approvals - The U.S. Securities and Exchange Commission (SEC) declared effective the registration statement on Form F-4 regarding the merger on July 21, 2025 [3]. Group 3: Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders, with drug development programs targeting Tourette Syndrome, Alzheimer's disease, and autism spectrum disorder [4]. - The company also has a controlling interest in a subsidiary that sells hemp seed oil-based products on Amazon [4].

Core Insights - SciSparc Ltd. has filed a new international patent application in collaboration with Clearmind Medicine Inc. for a combination therapy targeting obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) [1][2][3] Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders and rare diseases, with a portfolio that includes cannabinoid pharmaceuticals [4] - The company is currently developing drugs such as SCI-110 for Tourette Syndrome and SCI-210 for autism and status epilepticus [4] Industry Context - Obesity affects over 890 million people globally and is a significant risk factor for chronic conditions, while non-alcoholic fatty liver disease (NAFLD) impacts more than 30% of the adult population [2] - There is a limited number of treatment options available for these health challenges, highlighting the potential market opportunity for innovative therapies [2]

Group 1 - SciSparc Ltd. has regained compliance with Nasdaq Listing Rule 5550(a)(2) after its ordinary shares maintained a minimum bid price of $1.00 per share for 10 consecutive business days [1][2] - The compliance determination by Nasdaq indicates that the prior bid price deficiency matter is now closed [2] - SciSparc is a clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders and rare diseases, with a portfolio that includes drug development programs for Tourette Syndrome, Alzheimer's disease, autism, and status epilepticus [3] Group 2 - The company is led by an experienced team of senior executives and scientists, emphasizing its expertise in cannabinoid pharmaceuticals [3] - SciSparc also has a controlling interest in a subsidiary that sells hemp seed oil-based products on the Amazon.com Marketplace [3]

Company Overview - SciSparc Ltd. is a specialty clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders and rare diseases [6] - The company is engaged in drug development programs including SCI-110 for Tourette Syndrome and SCI-210 for autism and status epilepticus, utilizing cannabinoid pharmaceuticals [6] Reverse Share Split Announcement - The company announced a one-for-twenty one (1-for-21) reverse share split effective July 3, 2025, reducing the number of outstanding shares from approximately 11,225,751 to about 534,600 [1][4] - Following the reverse share split, approximately 516,727 shares will be publicly held, and the shares will continue to trade on the Nasdaq under the symbol "SPRC" [1] Shareholder Impact - The reverse share split will affect all shareholders uniformly, maintaining their percentage of ownership, with minor adjustments for fractional shares [4] - Fractional shares will not be issued; instead, they will be rounded to the nearest whole share [4] Share Capital and Options - The reverse share split will not adjust the authorized share capital, which remains at 75,000,000 Ordinary Shares [3] - There will be proportionate adjustments to the exercise price and the number of shares for all outstanding options and warrants [4] Shareholder Actions - Shareholders holding shares in book-entry form or through brokerage accounts do not need to take any action as the exchange will be processed automatically [5]

Core Viewpoint - SciSparc Ltd. has announced the publication of a Japanese divisional patent for a novel pharmaceutical combination of paracetamol and palmitoylethanolamide (PEA), which may provide enhanced pain and fever relief with lower doses and fewer side effects compared to traditional paracetamol use [1][2]. Group 1: Patent and Innovation - The newly published patent introduces a combination of paracetamol and PEA that could lead to safer and more effective treatment options for millions globally [2]. - The combination aims to reduce the required dosage of paracetamol, thereby minimizing risks such as liver damage while improving outcomes for various types of pain and fever [3]. Group 2: Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders and rare diseases, with a portfolio that includes cannabinoid pharmaceuticals [4]. - The company is currently engaged in drug development programs targeting conditions such as Tourette Syndrome, Alzheimer's disease, autism, and status epilepticus [4].

Core Insights - SciSparc Ltd. has announced a collaboration with Clearmind Medicine Inc. that has resulted in a European patent application for a combination treatment targeting cocaine addiction [1][4] - The patent application is based on preclinical trial results showing that Clearmind's MEAI significantly reduces cocaine-induced craving in animal models [2] - Further research indicates that MEAI specifically targets drug-related compulsions without impairing responses to natural rewards, suggesting a focused mechanism of action [3] Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company specializing in cannabinoid pharmaceuticals, with ongoing drug development programs for conditions such as Tourette Syndrome, Alzheimer's disease, and autism [5] - Clearmind Medicine Inc. is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics for health issues like alcohol use disorder, holding a portfolio of 19 patent families and 31 granted patents [6]

Core Insights - SciSparc Ltd. has announced a collaboration with Clearmind Medicine Inc. leading to the filing of a new international patent application for a treatment targeting anorexia, bulimia, and other eating disorders [1][2] Company Overview - SciSparc Ltd. is a specialty clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders, with a portfolio that includes cannabinoid pharmaceuticals [4] - The company is engaged in drug development programs targeting conditions such as Tourette Syndrome, Alzheimer's disease, and autism spectrum disorder [4] Collaboration Details - The patent application involves the use of 3-Methylmethcathinone (3-MMC) in combination with SciSparc's Palmitoylethanolamide (PEA), aiming to address neurobiological and psychological factors associated with eating disorders [2] Industry Context - Eating disorders are serious mental health conditions affecting up to 70 million people globally, with a prevalence increase from 3.4% to 7.8% between 2000 and 2018 [3] - These disorders are among the top ten leading causes of disability among young women and have one of the highest mortality rates compared to other mental disorders [3] Clearmind Medicine Overview - Clearmind Medicine Inc. is a clinical-stage psychedelic pharmaceutical biotech company focused on developing psychedelic-derived therapeutics for health issues like alcohol use disorder [5] - The company holds a portfolio of nineteen patent families, including 31 granted patents, and aims to expand its intellectual property [6]

Financial Performance - The company incurred significant net losses of approximately $7.5 million for the year ended December 31, 2024, $5.9 million for 2023, and $2.6 million for 2022, with an accumulated deficit of approximately $75 million as of December 31, 2024[52]. - As of December 31, 2024, the company had cash of approximately $2.1 million and working capital of approximately $4.9 million, indicating a need for substantial additional funding to continue operations[60]. - The company may need to seek additional funds sooner than planned due to changing operating plans and market conditions[60]. Revenue Generation - The company has not generated any revenue from the sale of its pharmaceutical product candidates and does not expect material revenues from its early commercialization efforts for CannAmide™[56]. - The company’s ability to generate revenue and achieve profitability depends on successfully completing the development and commercialization of its pharmaceutical product candidates[56]. - The potential addressable patient population for the company's pharmaceutical product candidates may be smaller than anticipated, adversely affecting revenue[122]. Research and Development - The company anticipates significant expenses related to the research and development of its product candidates, regulatory approvals, and establishing a sales and marketing infrastructure[54]. - The company has not yet commenced pivotal clinical studies for any product candidate, which may delay commercialization efforts for several years[53]. - The company may face difficulties in enrolling patients for clinical studies, which could delay or prevent the studies of its pharmaceutical product candidates[79]. Regulatory Challenges - The company plans to seek regulatory approval for its pharmaceutical product candidates in the United States and the European Union, but the approval process is lengthy and unpredictable[69]. - The company has not submitted marketing applications to the FDA or comparable foreign regulatory authorities, which poses a risk to its ability to commercialize its product candidates[68]. - Future legislative and regulatory proposals may materially impact the FDA's ability to operate, potentially slowing the review and approval of new products, adversely affecting the company's business[74]. Competition and Market Risks - The pharmaceutical industry is highly competitive, and the company may face patent litigation and mandatory delays in approval of its potential future NDAs[86]. - The company faces intense competition in the biotechnology and pharmaceutical industries, with many competitors potentially having greater financial and technical resources[125]. - The commercial success of product candidates will depend on market acceptance by physicians, patients, and third-party payors, which is uncertain[132]. Intellectual Property - The company holds a portfolio of seven granted patents and nine patent families, which are crucial for competitive positioning[151]. - The company may face challenges in enforcing intellectual property rights due to the repurposed nature of some drug substances, which could lead to competition from existing pharmaceutical products[157]. - Changes in patent laws could adversely affect the value and scope of the company's patent protections, impacting business operations[166]. Operational Risks - The company relies on third-party contract research organizations (CROs) for clinical studies, and any failure in their performance could delay regulatory approval[111]. - The company does not have internal manufacturing capabilities and relies on third parties for active pharmaceutical ingredients (API), which poses risks to supply continuity[114]. - The company may face challenges in recruiting additional employees and consultants, which could disrupt operations[179]. E-commerce Operations - Wellution, acquired in September 2022, sells hemp-based products on Amazon Marketplace, but management has limited prior experience in eCommerce operations[194]. - The company relies on sophisticated information technologies and systems for its operations, necessitating continuous improvements to maintain competitiveness[197]. - The eCommerce operations are vulnerable to risks related to online payment methods, including potential increases in transaction fees and compliance challenges[217]. Proposed Merger with AutoMax - The proposed merger with AutoMax is expected to result in AutoMax shareholders owning approximately 49.99% of the combined company on a fully-diluted basis[236]. - If the merger is not consummated, the company's share price could decline due to the associated risks and uncertainties[240]. - The company has incurred and expects to continue incurring significant expenses related to the proposed Merger with AutoMax, regardless of whether the Merger is completed[241].

Core Insights - SciSparc Ltd. has announced a collaboration with Clearmind Medicine Inc. resulting in a patent application for a combination treatment targeting cocaine addiction [1][4] - The patent application is based on preclinical trial results showing that Clearmind's MEAI significantly reduces cocaine-induced craving in animal models [2] - Further research indicates that MEAI specifically targets drug-related compulsions without impairing responses to natural rewards, suggesting a focused mechanism of action [3] Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company specializing in cannabinoid pharmaceuticals, with ongoing drug development programs targeting various conditions including Tourette Syndrome, Alzheimer's disease, pain, and autism spectrum disorder [5] - Clearmind Medicine Inc. is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics for health issues like alcohol use disorder [6] - Both companies are actively expanding their intellectual property portfolios, with Clearmind holding nineteen patent families and 31 granted patents [7]